Search results for "Peg"

showing 10 items of 460 documents

Desorganización del apego y el trastorno traumático del desarrollo (ttd)

2014

Abstract:DISRUPTION OF ATTACHMENT AND TRAUMATIC DISORDER OF DEVELOPMENTQuality development of family members depends on the quality of relationships they have established. From this developmental perspective the early parent-child interactions are a central aspect of Bowlby’s attachment theory. Mary Ainsworth allows us to establish a classification of attachment behaviors and Main and Solomon bring us under the name of disorganized attachment more complex and disturbing profiles of relations between parents and children. These relationships should be asymmetric and have a unique sense. In this paper we show the contributions related to disorganized attachment, its relationship to personalit…

media_common.quotation_subjectPersonality development05 social sciencesPerspective (graphical)lcsh:BF1-990050109 social psychologydesarrollo traumáticoapego050105 experimental psychologydesorganización del apegoQuality developmentDevelopmental psychologylcsh:PsychologydisociaciónAttachment theory0501 psychology and cognitive sciencesQuality (business)Psychologymedia_commonINFAD
researchProduct

Evaluación del riesgo en humedales costeros mediterráneos de la presencia de contaminantes químicos orgánicos = Evaluation of the risk in Mediterrane…

2008

El rápido incremento de la población urbana ha traído asociado una intensa presión en el medioambiente circundante. Actualmente, la franja costera en la mayoría de países europeos es el área que ha experimentado un mayor desarrollo socioeconómico. Algunas pinceladas obtenidas de distintas fuentes dan una idea global de la importancia del crecimiento demográfico de estas zonas. Hoy en día, 3 mil millones de personas –alrededor de la mitad de la población mundial- viven a menos de 200 kilómetros de la costa. Dos quintas partes de las ciudades con poblaciones de entre 1 y 10 millones están localizadas cerca de la costa. En Bélgica, Portugal y España, la densidad de población en los 10 kilómetr…

medicamentosPego-OlivasuelossedimentosmarjalsedimentsUNESCO::CIENCIAS MÉDICAS ::Ciencias de la Nutrición ::Toxicidad de los alimentospharmaceuticalsaguasdrugs:CIENCIAS MÉDICAS ::Ciencias de la Nutrición ::Toxicidad de los alimentos [UNESCO]AlbuferawetlandswatersmarshUNESCO::CIENCIAS DE LA TIERRA Y DEL ESPACIO::Hidrología::Calidad de las aguashumedalesdrogas:CIENCIAS DE LA TIERRA Y DEL ESPACIO::Hidrología::Calidad de las aguas [UNESCO]LC-MS/MSsoils
researchProduct

Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SA…

2021

The main contraindication to the anti-SARS CoV2 vaccine is an anaphylactic reaction to a vaccine component. The need to vaccinate allergic people who are at higher risk can be of public health interest and this report shows a case of an allergic reaction to PEG of a HCW who had received the first dose of anti-SARS CoV2 vaccine. For 5 h after the administration of the vaccine, she had the appearance of erythematous spots on the face and neck, and a feeling of a slurred mouth and hoarseness. In order to treat the event, she was administered 8 mg intravenous dexamethasone, 1 vial intravenous chlorphenamine maleate, 250 mL intravenous 0.9% NaCl, and conventional oxygen therapy (2 L/min) with co…

medicine.medical_specialtyAllergyImmunologyadverse reactionCase ReportVial03 medical and health sciences0302 clinical medicineInternal medicinevaccineDrug DiscoverymedicineanaphylaxisPharmacology (medical)030212 general & internal medicineAdverse effectContraindicationDexamethasonePharmacologym-RNA vaccinebusiness.industrySARS CoV2Rmedicine.diseasePEGAdverse reaction Anaphylaxis Basophil activation test Contraindica-tion M-RNA vaccine PEG SARS CoV2 VaccineVaccinationInfectious Diseases030228 respiratory systembasophil activation testMedicinebusinessAnaphylaxisAdverse drug reactioncontraindicationmedicine.drugVaccines
researchProduct

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

2012

Abstract Background Ovarian cancer (OC) is the sixth most common cancer in women. Currently, carboplatin/paclitaxel ± bevacizumab is the cornerstone of front-line treatment. Conversely, the therapeutic options for recurrent or progressive disease are not well defined. For platinum-sensitive patients the best therapeutic approach is still a re-challenge with a platinum-based regimen. Pegylated liposomal doxorubicin (PLD), is considered one of the most active therapeutic options for recurrent or progressive OC. In this retrospective mono-institutional analysis, we evaluated the impact of PLD on the outcome of OC patients. Patients and methods We performed the retrospective study on a cohort o…

medicine.medical_specialtyBevacizumabUrologySecond line treatmentchemistry.chemical_compoundOvarian cancerPegylated liposomal doxorubicinObstetrics and GynaecologymedicineStage (cooking)Systemic chemotherapyGynecologyPlatinum refractory patientsbusiness.industryResearchObstetrics and GynecologyCancerRetrospective cohort studymedicine.diseaseCarboplatinRegimenenzymes and coenzymes (carbohydrates)OncologychemistryPlatinum refractory patientlipids (amino acids peptides and proteins)Ovarian cancerbusinessProgressive diseasemedicine.drugJournal of ovarian research
researchProduct

Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a s…

2020

Purpose: to conduct a systematic review with network meta‐analysis (NMA) of randomized clinical trials (RCTs) comparing panretinal photocoagulation (PRP) versus anti‐vascular endothelial growth factor (VEGF) treatment alone or in combination with PRP, for proliferative diabetic retinopathy (PDR).Methods: PubMed, Medline and Embase databases were searched for RCTs comparing PRP versus intravitreal anti‐VEGF therapy and/or combined PRP and intravitreal anti‐VEGF for PDR. The primary outcome measures were the mean best corrected visual acuity (BCVA) change and the regression of neovascularization. Mean change of central macular thickness (CMT), the subgroup analyses of patients without diabeti…

medicine.medical_specialtyBevacizumabgenetic structurespegaptanibmedicine.medical_treatmentPegaptanibNetwork Meta-AnalysisVisual AcuityVitrectomyAngiogenesis Inhibitorsbevacizumablaw.inventionNeovascularization03 medical and health sciences0302 clinical medicineRandomized controlled trialaflibercept; bevacizumab; intravitreal anti-VEGF; panretinal photocoagulation; pegaptanib; proliferative diabetic retinopathy; ranibizumabintravitreal anti-VEGFlawOphthalmologyVitrectomymedicineHumansranibizumabAfliberceptDiabetic RetinopathyLaser Coagulationbusiness.industryafliberceptGeneral MedicineDiabetic retinopathymedicine.diseasepanretinal photocoagulationeye diseasesOphthalmologyIntravitreal Injections030221 ophthalmology & optometrysense organsRanibizumabmedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugproliferative diabetic retinopathy
researchProduct

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct

Current and future HCV therapy: do we still need other anti-HCV drugs?

2014

Eradication of hepatitis C virus (HCV) infection, at least in compensated patients, can help improve the outcomes of liver disease such as cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation, as well as perhaps extra-hepatic complications such as diabetes and cardiovascular risk. In the past few years, the landscape of antiviral therapy has evolved at a breathtaking pace from pegylated interferon (PEG-IFN) plus ribavirin (RBV) (PEG-IFN/RBV) to IFN-based strategies combining direct acting antivirals (DDAs) with PEG-IFN/RBV and finally IFN-free combinations of DAAs. In particular with these most recent developments, treatment regimens have become shorter, safer and even more e…

medicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationChronic hepatitis Cmedicine.disease_causeAntiviral AgentsLiver diseasechemistry.chemical_compoundPegylated interferonmedicineHumansDisease EradicationIntensive care medicineAntiviral AgentHepaciviruHepatologybusiness.industryMedicine (all)Ribavirinmedicine.diseaseHepatitis CClinical researchchemistryHepatocellular carcinomaImmunologyDrug Therapy CombinationDirect antiviral agentTherapybusinessHumanmedicine.drugLiver International
researchProduct

Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects

2011

Introduction: The goal of antiviral therapy in patients with chronic hepatitis C is to slow or halt the progression of fibrosis and prevent the development of cirrhosis. Accordingly, antiviral treatment is proposed for a large population of patients with chronic hepatitis. Areas covered: The standard-of-care for chronic hepatitis C is the combination of pegylated IFN (PEG-IFN) and ribavirin. The use of these drugs has been correlated with a range of adverse effects, including influenza-like symptoms, hematological changes and neuropsychiatric disturbances. The effects of these adverse events associated with PEG-IFN therapy are manifold and are a major reason why patients decline or stop the…

medicine.medical_specialtyCirrhosisMedication Therapy ManagementPegylated interferon αInterferon alpha-2Antiviral AgentsPolyethylene Glycolschemistry.chemical_compoundFibrosisRibavirinmedicineHumansPharmacology (medical)In patientIntensive care medicineAdverse effectbusiness.industryRibavirinInterferon-alphaGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant ProteinsClinical PracticeTreatment OutcomechemistryPhysical therapyhepatitis Cbusiness
researchProduct

PIN31: THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HE…

2003

medicine.medical_specialtyCost effectivenessbusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthGastroenterologychemistry.chemical_compoundchemistryChronic hepatitisInternal medicinemedicinebusinessInterferon alfamedicine.drugPeginterferon alfa-2aValue in Health
researchProduct

Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a…

2008

medicine.medical_specialtyCrohn's diseasetherapybusiness.industryGastroenterologyCompassionate Usemedicine.diseaseCertolizumabInfliximabClinical trialPharmacotherapyRefractoryCertolizumab Crohn's disease RefractoryInternal medicinemedicineImmunology and AllergyCertolizumab pegolbusinessmedicine.drug
researchProduct